MedTrace Logo

Individualization of the Immunological Risk Based on Selective Biomarkers in Living-donor Renal Recipients

NCT03465397 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 164

Last updated 2021-01-08

No results posted yet for this study

Summary

This is a clinical trial comparing the immunosuppressive treatment determined according to two biomarkers, donor-specific IFN-γ ELISPOT and Mismatch of HLA between donor and recipient, in patients undergoing low immunological risk live donor kidney transplantation

Conditions

  • Kidney Transplant Failure and Rejection

Interventions

DIAGNOSTIC_TEST

biomarkers driven immunosuppressive therapy

the immunosuppressive treatment of the patients is determined according to the result of 2 biomarkers of immunological risk

Sponsors & Collaborators

  • Department of Health, Generalitat de Catalunya

    collaborator OTHER_GOV

  • ORIOL BESTARD

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-10
Primary Completion
2021-11-30
Completion
2021-11-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03465397 on ClinicalTrials.gov